Scott Schliebner, MPH Senior Vice President, Center for Rare Diseases, PRA Health Sciences
Mr. Schliebner is a clinical strategist with a 25-year background in clinical drug development focused on rare diseases, orphan drugs, and advanced therapeutics. He is committed to developing patient-centered research paradigms that reduce the burden of clinical trial participation and bring new therapies to rare disease patients faster. Committed to collaborative efforts to further rare disease drug development, Mr. Schliebner is actively engaged in fostering partnerships between patient-focused organizations, patients, investigators, and industry. Mr. Schliebner has held leadership positions across non-profit, academic, and industry settings and most recently served as Chief Operating Officer for a cancer research institute focused on accelerating the development of new targeted therapies. He holds a Master’s Degree in Public Health (MPH) and completed a Graduate Research Fellowship at The National Institutes of Health.